Results 41 to 50 of about 737,831 (320)

The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. [PDF]

, 2011
Encapsulation of drugs within nanocarriers that selectively target malignant cells promises to mitigate side effects of conventional chemotherapy and to enable delivery of the unique drug combinations needed for personalized medicine.
Ashley, Carlee E, Brinker, C Jeffrey, Brown, Page A, Carnes, Eric C, Carroll, Nick J, Carter, Mark B, Chackerian, Bryce, Dunphy, Darren R, Durfee, Paul N, Evans, Deborah G, Hanna, Tracey N, Jiang, Xingmao, Liu, Juewen, Padilla, David, Parikh, Atul N, Peabody, David S, Petsev, Dimiter N, Phillips, Brandy, Phillips, Genevieve K, Wharton, Walker, Willman, Cheryl L   +20 more
core   +2 more sources

A Bayesian seamless phase I-II trial design with two stages for cancer clinical trials with drug combinations

, 2020
The use of drug combinations in clinical trials is increasingly common during the last years since a more favorable therapeutic response may be obtained by combining drugs.
Jiménez, José L., Kim, Sungjin, Tighiouart, Mourad   +2 more
core   +1 more source

Time-programmable drug dosing allows the manipulation, suppression and reversal of antibiotic drug resistance in vitro [PDF]

, 2017
Multi-drug strategies have been attempted to prolong the efficacy of existing antibiotics, but with limited success. Here we show that the evolution of multi-drug-resistant Escherichia coli can be manipulated in vitro by administering pairs of ...
Cronin, Leroy, Furusawa, Chikara, Galiñanes Reyes, Sabrina Galiñanes, Horinouchi, Takaaki, Tsuda, Soichiro, Yoshida, Mari   +5 more
core   +1 more source

Drug Repurposing for Schistosomiasis: Combinations of Drugs or Biomolecules [PDF]

Pharmaceuticals, 2018
Schistosomiasis is a major neglected tropical disease. Control of schistosomiasis currently relies on a single drug, praziquantel, and despite its efficacy against the all schistosome species that parasitize humans, it displays some problematic drawbacks and alone is ineffective in counteracting adverse pathologies associated with infection.
Paul J. Brindley, Fátima Gärtner, Fátima Gärtner, Maria João Gouveia, Nuno Vale, José Manuel Correia da Costa, José Manuel Correia da Costa   +6 more
openaire   +4 more sources

Systematic Prediction of Antifungal Drug Synergy by Chemogenomic Screening in Saccharomyces cerevisiae

Frontiers in Fungal Biology, 2021
Since the earliest days of using natural remedies, combining therapies for disease treatment has been standard practice. Combination treatments exhibit synergistic effects, broadly defined as a greater-than-additive effect of two or more therapeutic ...
Hamid Gaikani, Hamid Gaikani, Andrew M. Smith, Anna Y. Lee, Guri Giaever, Corey Nislow, Corey Nislow   +6 more
doaj   +1 more source

Improved Network Performance via Antagonism: From Synthetic Rescues to Multi-drug Combinations [PDF]

, 2010
Recent research shows that a faulty or sub-optimally operating metabolic network can often be rescued by the targeted removal of enzyme-coding genes--the exact opposite of what traditional gene therapy would suggest.
Adilson E. Motter, Baba, Blagosklonny, Bollenbach, Bourgeois, Burgard, Burgard, Cagatay, Chait, Cun, Dancey, Duarte, Edwards, Feist, Fischer, Fong, Fong, Fong, Fong, Fraenkel, Gerdes, Giaever, Goebl, Harrison, Hashimoto, Hegreness, Henry, Herring, Hilgetag, Hilgetag, Hillenmeyer, Hopkins, Huttenlocher, Huttenlocher, Isalan, Kauffman, Keiser, Kim, Kitano, Kupiec, Ma, Miller, Motter, Motter, Nishikawa, Olson, Palsson, Papp, Pharkya, Reguly, Segre, Segre, Shlomi, Timmermans, Wagner, Yeh, Yildirim, Yngvadottir, Zamboni   +58 more
core   +3 more sources

Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. [PDF]

, 2020
Hundreds of trials are being conducted to evaluate combination of newer targeted drugs as well as immunotherapy. Our aim was to compare efficacy and safety of combination versus single non-cytotoxic anticancer agents. We searched PubMed (01/01/2001 to 03/
Barkauskas, Donald A, De Melo Gagliato, Débora, Jardim, Denis L, Kurzrock, Razelle, Nikanjam, Mina   +4 more
core   +1 more source

PINet 1.0: A pathway network-based evaluation of drug combinations for the management of specific diseases

Frontiers in Molecular Biosciences, 2022
Drug combinations can increase the therapeutic effect by reducing the level of toxicity and the occurrence of drug resistance. Therefore, several drug combinations are often used in the management of complex diseases.
Yongkai Hong, Dantian Chen, Yaqing Jin, Mian Zu, Yin Zhang   +4 more
doaj   +1 more source

Newer drug combinations for malaria [PDF]

BMJ, 2004
May be impractical unless diagnostic accuracy can be improved Resistance of parasites to cheap, first line malaria drugs is a major obstacle to reducing the more than one million deaths due to malaria each year worldwide. Comparing the number of parasitologically confirmed cases of malaria with those that are presumptively diagnosed reveals ...
Guy Barnish, James Iboro, Imelda Bates
openaire   +3 more sources

Dynamic Rearrangement of Cell States Detected by Systematic Screening of Sequential Anticancer Treatments [PDF]

, 2017
Signaling networks are nonlinear and complex, involving a large ensemble of dynamic interaction states that fluctuate in space and time. However, therapeutic strategies, such as combination chemotherapy, rarely consider the timing of drug perturbations ...
Blicher Bjerregård, Mathias, Cox, Thomas R., Erler, Janine T., Ferkinghoff-Borg, Jesper, Koplev, Simon, Linding, Rune, Longden, James, Pedersen, Jesper T., Sommer, Morten Otto Alexander, Voellmy, Franziska   +9 more
core   +3 more sources